Crossmark

Feasibility of randomizing Danish citizens aged 65–79 years to high-dose quadrivalent influenza vaccine vs. standard-dose quadrivalent influenza vaccine in a pragmatic registry-based setting: rationale and design of the DANFLU-1 Trial

Crossref DOI link: https://doi.org/10.1186/s40814-022-01044-w

Published Online: 2022-04-21

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Johansen, Niklas Dyrby

Modin, Daniel

Nealon, Joshua

Samson, Sandrine

Salamand, Camille

Larsen, Carsten Schade

Claggett, Brian L.

Solomon, Scott D.

Landray, Martin J.

Gislason, Gunnar H.

Køber, Lars

Jensen, Jens Ulrik Stæhr

Sivapalan, Pradeesh

Vestergaard, Lasse Skafte

Valentiner-Branth, Palle

Krause, Tyra Grove

Biering-Sørensen, Tor
Funding

Funding for this research was provided by:

Sanofi Pasteur (N/A)
License Information

Text and Data Mining valid from 2022-04-21

Version of Record valid from 2022-04-21
More Information

Article History

Received: 1 March 2022

Accepted: 4 April 2022

First Online: 21 April 2022

Declarations

:

: The study was approved by the ethics committee in the Capital Region of Denmark (ref. H-21035316). All participants will provide written informed consent.

: Not applicable.

: Dr. Nealon, Dr. Samson, and Dr. Salamand are Sanofi Pasteur Employees and may hold shares.Dr. Biering-Sørensen has received speaker fees and served on advisory boards for Sanofi Pasteur.Dr. Solomon has received research grants and consulting fees from Sanofi Pasteur.N.D. Johansen, D. Modin, C.S. Larsen, B.L. Claggett, M.J. Landray, G.H. Gislason, L. Køber. J.U.S. Jensen, P. Sivapalan, L.S. Vestergaard, P. Valentiner-Branth, and T.G. Krause have no competing interests.

Document is current

Any future updates will be listed below